GlassScriptPhysician profile
Mark Norman Sadoff
NPI 1497784946
$4,513.81
in general payments reported to CMS, 2019-2025
41 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $632 · 2021: $1,150 · 2022: $626 · 2023: $425 · 2024: $386 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,278.72 | 2019-2022 | |
| Abbvie INC. | $611.76 | 2021-2025 | Botox, Ubrelvy |
| Medtronic, INC. | $306.72 | 2021-2022 | |
| Ucb, INC. | $276.33 | 2020-2025 | Nayzilam |
| Amgen INC. | $235.48 | 2021-2025 | Uplizna |
| Medtronic Vascular, INC. | $214.63 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $159.82 | 2023-2025 | Austedo, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $126.29 | 2020-2025 | |
| Pfizer INC. | $103.39 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $89.59 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $89.12 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $84.93 | 2019-2022 | |
| Eisai INC. | $83.85 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $69.48 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $60.70 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sadoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.